XENON PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.5 USD | +1.00% |
|
+1.55% | -12.07% |
| 19/04 | Xenon Pharmaceuticals Inc. Announces Board Resignations | CI |
| 11/03 | Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM |
Chart calendar Xenon Pharmaceuticals Inc.
afdd4923efe03a1cb07e6af8a7d497c._mXnZTkWKp9hiuPfUEAcz2wMhMaCKL-UyEVTEZzVHMk.zACgAwB9G-YK3c6XBCdJmjRUtvbxb-3eunURXqyfd4SqFZMyUV5z7RX_0w~501c1489293360326a273a51c21b09ad
Upcoming events on Xenon Pharmaceuticals Inc.
Past events on Xenon Pharmaceuticals Inc.
| 16/04/2024 07:00 pm | Bloom Burton & Co. Healthcare Investor Conference |
| 12/04/2024 12:30 am | Needham Healthcare Conference |
| 19/03/2024 10:00 pm | Stifel Virtual CNS Conference |
| 11/03/2024 08:50 pm | Leerink Partners Global Biopharma Conference |
| 01/03/2024 03:00 am | Q4 2023 Earnings Call |
| 01/03/2024 02:48 am | Q4 2023 Earnings Release |
| 08/01/2024 10:30 pm | JPMorgan Healthcare Conference |
| 04/12/2023 12:30 am | American Epilepsy Society Meeting |
| 01/12/2023 | American Epilepsy Society Meeting - Poster No:2.259 |
| 01/12/2023 | American Epilepsy Society Meeting - Poster No:2.260 |
| 01/12/2023 | American Epilepsy Society Meeting - Poster No:1.277 |
| 27/11/2023 07:00 pm | XEN1101 Phase 2 X-NOVA Clinical Trial Results Call |
| 09/11/2023 03:00 am | Q3 2023 Earnings Call |
| 09/11/2023 02:31 am | Q3 2023 Earnings Release |
| 11/10/2023 11:55 pm | Jefferies Inaugural Biotech CNS/Neuro Summit |
| 21/09/2023 01:50 am | TD Cowen Novel Mechanisms in Neuropsychiatry Summit |
| 19/09/2023 09:00 pm | Investor Meeting |
| 06/09/2023 11:45 pm | Wells Fargo Healthcare Conference |
| 02/09/2023 | International Epilepsy Congress |
| 10/08/2023 02:00 am | Q2 2023 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 6,83 19,5 -64.98% | 32,2 30,2 6.45% | 18,4 20,7 -11.02% | 9,43 12,2 -22.63% | 0,00 2,20 - | 2,39 |
|
EBITDA Million USD | Released Forecast Spread | -42,4 -24,2 -75.22% | 0,00 0,00 - | 0,00 0,00 - | -128 -113 -12.58% | -211 -208 -1.12% | -215 |
|
EBIT Million USD | Released Forecast Spread | -42,8 -31,9 -34.29% | -31,3 -33,3 6% | -79,0 -73,3 -7.83% | -129 -124 -4.29% | -214 -214 -0.23% | -242 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -41,6 -30,6 -35.86% | -29,1 -30,8 5.52% | -78,9 -71,3 -10.59% | -125 -127 1.56% | -183 -188 2.83% | -218 |
|
Net income Million USD | Released Forecast Spread | -40,0 -30,1 -32.87% | -28,0 -30,1 6.86% | -77,1 -70,4 -9.48% | -125 -127 1.26% | -182 -190 3.91% | -220 |
|
EPS USD | Released Forecast Spread | -1,54 -1,05 -47.23% | -0,81 -0,87 7.05% | -1,77 -1,65 -7.2% | -2,06 -2,08 0.82% | -2,73 -2,82 3.34% | -2,96 |
| Announcement Date | 09/03/20 | 01/03/21 | 01/03/22 | 01/03/23 | 29/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,74 5,69 -34.27% | 8,77 8,84 -0.87% | 0,54 3,25 -83.5% | 0,13 3,02 -95.63% | 0,00 2,46 - | 0,00 0,53 - | 0,00 0,40 - | 0,00 1,35 - | 0,00 2,01 - | 0,00 | 0,00 | 0,00 | 2,38 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -17,0 -23,5 27.64% | -29,9 -29,6 -1.09% | -37,8 -27,8 -35.85% | -42,8 -26,8 -59.87% | -48,7 -34,6 -40.82% | -55,0 -36,5 -50.83% | -54,0 -47,5 -13.63% | -52,8 -47,8 -10.58% | -52,8 | -53,4 | -54,1 | -44,1 | ||
|
EBIT Million USD | Released Forecast Spread | -24,8 -18,9 -31.09% | -17,4 -21,7 20.05% | -30,3 -27,3 -11.22% | -38,1 -31,8 -19.91% | -43,3 -37,6 -15.21% | -49,1 -41,3 -18.76% | -55,6 -47,4 -17.43% | -55,7 -54,4 -2.38% | -53,7 -54,4 1.35% | -56,2 | -59,5 | -63,7 | -65,3 | -57,9 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -25,1 -18,2 -37.77% | -20,1 -22,5 10.63% | -31,2 -27,5 -13.57% | -37,7 -32,8 -15.2% | -36,3 -39,1 7.35% | -41,4 -41,4 -0.16% | -47,7 -46,8 -1.92% | -48,6 -51,3 5.16% | -44,9 -50,2 10.53% | -49,9 | -53,3 | -57,0 | -57,9 | -50,7 |
|
Net income Million USD | Released Forecast Spread | -25,1 -20,8 -20.6% | -19,4 -22,0 11.98% | -31,2 -27,3 -14.28% | -37,2 -33,1 -12.21% | -37,4 -39,0 4.06% | -41,7 -40,9 -1.9% | -47,5 -46,2 -2.83% | -48,5 -50,2 3.46% | -44,7 -52,2 14.23% | -50,4 | -53,6 | -57,6 | -59,2 | -50,7 |
|
EPS USD | Released Forecast Spread | -0,48 -0,37 -31.06% | -0,35 -0,42 17.16% | -0,55 -0,49 -12.03% | -0,57 -0,52 -8.66% | -0,57 -0,59 3.36% | -0,63 -0,64 1.33% | -0,72 -0,71 -2.08% | -0,73 -0,77 4.7% | -0,64 -0,76 15.8% | -0,67 | -0,71 | -0,76 | -0,78 | -0,75 |
| Announcement Date | 01/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 01/03/23 | 09/05/23 | 09/08/23 | 08/11/23 | 29/02/24 | - | - | - | - | - |
More events
Past sector events for Xenon Pharmaceuticals Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- XENE Stock
- Calendar Xenon Pharmaceuticals Inc.
